Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AC-(D)Phe-pro-borolys-OH is an experimental small molecule dipeptide containing a boronic acid moiety. It acts as a potent, covalent inhibitor of prothrombin (also known as coagulation factor II), specifically targeting the active site of the enzyme. The compound has been structurally characterized in complex with human alpha-thrombin, indicating its mechanism involves direct inhibition of thrombin activity by binding to its catalytic site. This mechanism suggests potential utility as an anticoagulant or antithrombotic agent, though it has not advanced beyond preclinical or early experimental stages and is not approved for any indication[1][6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AC-(D)Phe-pro-borolys-OH.